NCT06122662Phase 2, phase 3Completed

AMX0035 and Progressive Supranuclear Palsy

Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09-30Actual
Enrollment · participants139Actual
Source updated2026-04-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 110 participants (planned). After: 139 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 1 Apr 2026. After: 30 Sep 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview